US healthcare enters 2024 with transparency momentum to build on

Both providers and payers upped their game on price transparency in 2023.

The year closed with almost 91% of affected hospitals posting machine-readable files, while the number of payers posting data rose from 67 to more than 200.

The progress gets fleshed out in a report published Jan. 4 by the healthcare software supplier Turquoise Health.

The company also notes that, as of Dec. 15, 83% of hospitals were sharing negotiated rates online.

Some 562 hospitals entered the posting arena in 2023, bringing the total to 6,357 hospitals (out of around 7,300 active hospitals in the U.S.), according to data reported by Turquoise.

Here’s the breakdown of hospital counts with type of rates posted.

  • 5,763 hospitals (90.7%) have posted machine-readable files.
  • 5,280 hospitals (83.1%) are sharing negotiated rates.
  • 4,911 hospitals (77.3%) are sharing cash rates.
  • 5,109 hospitals (80.4%) are sharing surgery rates.
  • 5,134 hospitals (80.8%) are sharing imaging rates.
  • 5,170 hospitals (81.3%) are sharing rates for enrollees of Blue Cross Blue Shield, United Healthcare, Cigna, Aetna and Humana.
  • 4,137 hospitals (65.1%) are sharing diagnosis-related group (DRG) rates.
  • 4,412 hospitals (69.4%) are sharing drug rates.

“One theme that emerged from the 2023 price transparency landscape is consolidation,” the authors comment, noting that numerous bills were melded into the Lower Costs, More Transparency Act.

This bill, which passed the House of Representatives Dec. 11, “is expansive and stands to codify price transparency reporting for hospitals, payers, non-hospital entities and pharmacy benefit managers into law.”

While Lower Costs, More Transparency continues on to the Senate, Turquoise points out, all three current rules and laws—Hospital Final Rules, the Transparency in Coverage rule, and the No Surprises Act—remain in effect.

Read the rest.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.